Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ3 (PPAR γ3)-selective antagonists based on the helix12-folding inhibition hypothesis

Masao Ohashi, Kanae Gamo, Yuta Tanaka, Minoru Waki, Yoko Beniyama, Kenji Matsuno, Jun Wada, Masafumi Tenta, Jun Eguchi, Makoto Makishima, Nobuyasu Matsuura, Takuji Oyama, Hiroyuki Miyachi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptor γ3 (PPARγ3) antagonists are candidates for treatment of type 2 diabetes, obesity and osteoporosis. However, few rational design strategies are currently available. Here, we utilized the helix12 (H12)-folding inhibition hypothesis, in combination with our previously determined X-ray crystal structure of PPARγ3 agonist MEKT-21 (6) complexed with the PPARγ3 ligand-binding domain, to design and develop a potent phenylalkynyl amide-type PPARγ3 antagonist 9i, focusing initially on pinpoint structural modification of the propanoic acid moiety of 6. Since 9i retained very weak, but distinct, PPARγ3 agonist activity, we next modified the distal benzene ring of 9i, aiming to delete the residual PPARγ3 agonist activity while retaining the antagonist activity. Introduction of a chlorine atom at the 2-position of the distal benzene ring afforded 9p, which exhibited potent, PPARγ3-selective full antagonist activity without detectable agonist activity. We found that 9p stabilized the corepressor-PPARγ3 complex and suppressed basal PPARγ3 activity. This compound showed anti-adipogenesis activity at the cellular level. This agonist-antagonist switching concept based on the H12-folding inhibition hypothesis should also be applicable for designing other classes of PPARγ3 full antagonists.

Original languageEnglish
Pages (from-to)53-67
Number of pages15
JournalEuropean Journal of Medicinal Chemistry
Volume90
DOIs
Publication statusPublished - Jan 27 2015

Fingerprint

Peroxisome Proliferator-Activated Receptors
Structural design
Amides
Benzene
Co-Repressor Proteins
Adipogenesis
Chlorine
Medical problems
Type 2 Diabetes Mellitus
Osteoporosis
Obesity
Crystal structure
X-Rays
Ligands
X rays
Atoms

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology
  • Medicine(all)

Cite this

Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ3 (PPAR γ3)-selective antagonists based on the helix12-folding inhibition hypothesis. / Ohashi, Masao; Gamo, Kanae; Tanaka, Yuta; Waki, Minoru; Beniyama, Yoko; Matsuno, Kenji; Wada, Jun; Tenta, Masafumi; Eguchi, Jun; Makishima, Makoto; Matsuura, Nobuyasu; Oyama, Takuji; Miyachi, Hiroyuki.

In: European Journal of Medicinal Chemistry, Vol. 90, 27.01.2015, p. 53-67.

Research output: Contribution to journalArticle

Ohashi, Masao ; Gamo, Kanae ; Tanaka, Yuta ; Waki, Minoru ; Beniyama, Yoko ; Matsuno, Kenji ; Wada, Jun ; Tenta, Masafumi ; Eguchi, Jun ; Makishima, Makoto ; Matsuura, Nobuyasu ; Oyama, Takuji ; Miyachi, Hiroyuki. / Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ3 (PPAR γ3)-selective antagonists based on the helix12-folding inhibition hypothesis. In: European Journal of Medicinal Chemistry. 2015 ; Vol. 90. pp. 53-67.
@article{5caef013709d4060b65666e94caf9c0d,
title = "Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ3 (PPAR γ3)-selective antagonists based on the helix12-folding inhibition hypothesis",
abstract = "Peroxisome proliferator-activated receptor γ3 (PPARγ3) antagonists are candidates for treatment of type 2 diabetes, obesity and osteoporosis. However, few rational design strategies are currently available. Here, we utilized the helix12 (H12)-folding inhibition hypothesis, in combination with our previously determined X-ray crystal structure of PPARγ3 agonist MEKT-21 (6) complexed with the PPARγ3 ligand-binding domain, to design and develop a potent phenylalkynyl amide-type PPARγ3 antagonist 9i, focusing initially on pinpoint structural modification of the propanoic acid moiety of 6. Since 9i retained very weak, but distinct, PPARγ3 agonist activity, we next modified the distal benzene ring of 9i, aiming to delete the residual PPARγ3 agonist activity while retaining the antagonist activity. Introduction of a chlorine atom at the 2-position of the distal benzene ring afforded 9p, which exhibited potent, PPARγ3-selective full antagonist activity without detectable agonist activity. We found that 9p stabilized the corepressor-PPARγ3 complex and suppressed basal PPARγ3 activity. This compound showed anti-adipogenesis activity at the cellular level. This agonist-antagonist switching concept based on the H12-folding inhibition hypothesis should also be applicable for designing other classes of PPARγ3 full antagonists.",
author = "Masao Ohashi and Kanae Gamo and Yuta Tanaka and Minoru Waki and Yoko Beniyama and Kenji Matsuno and Jun Wada and Masafumi Tenta and Jun Eguchi and Makoto Makishima and Nobuyasu Matsuura and Takuji Oyama and Hiroyuki Miyachi",
year = "2015",
month = "1",
day = "27",
doi = "10.1016/j.ejmech.2014.11.017",
language = "English",
volume = "90",
pages = "53--67",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ3 (PPAR γ3)-selective antagonists based on the helix12-folding inhibition hypothesis

AU - Ohashi, Masao

AU - Gamo, Kanae

AU - Tanaka, Yuta

AU - Waki, Minoru

AU - Beniyama, Yoko

AU - Matsuno, Kenji

AU - Wada, Jun

AU - Tenta, Masafumi

AU - Eguchi, Jun

AU - Makishima, Makoto

AU - Matsuura, Nobuyasu

AU - Oyama, Takuji

AU - Miyachi, Hiroyuki

PY - 2015/1/27

Y1 - 2015/1/27

N2 - Peroxisome proliferator-activated receptor γ3 (PPARγ3) antagonists are candidates for treatment of type 2 diabetes, obesity and osteoporosis. However, few rational design strategies are currently available. Here, we utilized the helix12 (H12)-folding inhibition hypothesis, in combination with our previously determined X-ray crystal structure of PPARγ3 agonist MEKT-21 (6) complexed with the PPARγ3 ligand-binding domain, to design and develop a potent phenylalkynyl amide-type PPARγ3 antagonist 9i, focusing initially on pinpoint structural modification of the propanoic acid moiety of 6. Since 9i retained very weak, but distinct, PPARγ3 agonist activity, we next modified the distal benzene ring of 9i, aiming to delete the residual PPARγ3 agonist activity while retaining the antagonist activity. Introduction of a chlorine atom at the 2-position of the distal benzene ring afforded 9p, which exhibited potent, PPARγ3-selective full antagonist activity without detectable agonist activity. We found that 9p stabilized the corepressor-PPARγ3 complex and suppressed basal PPARγ3 activity. This compound showed anti-adipogenesis activity at the cellular level. This agonist-antagonist switching concept based on the H12-folding inhibition hypothesis should also be applicable for designing other classes of PPARγ3 full antagonists.

AB - Peroxisome proliferator-activated receptor γ3 (PPARγ3) antagonists are candidates for treatment of type 2 diabetes, obesity and osteoporosis. However, few rational design strategies are currently available. Here, we utilized the helix12 (H12)-folding inhibition hypothesis, in combination with our previously determined X-ray crystal structure of PPARγ3 agonist MEKT-21 (6) complexed with the PPARγ3 ligand-binding domain, to design and develop a potent phenylalkynyl amide-type PPARγ3 antagonist 9i, focusing initially on pinpoint structural modification of the propanoic acid moiety of 6. Since 9i retained very weak, but distinct, PPARγ3 agonist activity, we next modified the distal benzene ring of 9i, aiming to delete the residual PPARγ3 agonist activity while retaining the antagonist activity. Introduction of a chlorine atom at the 2-position of the distal benzene ring afforded 9p, which exhibited potent, PPARγ3-selective full antagonist activity without detectable agonist activity. We found that 9p stabilized the corepressor-PPARγ3 complex and suppressed basal PPARγ3 activity. This compound showed anti-adipogenesis activity at the cellular level. This agonist-antagonist switching concept based on the H12-folding inhibition hypothesis should also be applicable for designing other classes of PPARγ3 full antagonists.

UR - http://www.scopus.com/inward/record.url?scp=84910645520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910645520&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2014.11.017

DO - 10.1016/j.ejmech.2014.11.017

M3 - Article

C2 - 25461311

AN - SCOPUS:84910645520

VL - 90

SP - 53

EP - 67

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -